Jim Tananbaum, Foresite Capital CEO (Business Wire)
June 29, 2021 10:25 AM EDTUpdated July 2, 01:36 PM
Financing
Deals

Gilead, Fore­site take an un­known pan­dem­ic an­tivi­ral pub­lic in $250M SPAC deal

Jason Mast

Editor

The SPAC boom has pro­duced some sur­pris­ing deals but gen­er­al­ly speak­ing, peo­ple fol­low­ing the in­dus­try have at least heard of the com­pa­nies go­ing pub­lic. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Trump says he'll sign or­der on 'most fa­vored na­tion' drug price plans Mon­day

Lil­ly says fur­ther head-to-head tri­al da­ta back Zep­bound over No­vo’s We­govy

From deal to dis­as­ter: Drug­mak­ers face a changed Wash­ing­ton as Trump em­braces ‘most fa­vored na­tion’ prices

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

As­traZeneca re­ports Phase 3 win for Imfinzi; Roche to build new man­u­fac­tur­ing site in Chi­na

A service from the Financial Times